# OnCo record paper-imspire150-lancet-oncol-2023-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imspire150-lancet-oncol-2023-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imspire150-lancet-oncol-2023-update" ;
  schema:name "Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study"@en ;
  schema:description "Later report from the IMspire150 trial registered as NCT02908672, in The Lancet Oncology (2023); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-imspire150-lancet-oncol-2023-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(22)00687-8>, <https://pubmed.ncbi.nlm.nih.gov/36460017/>, <https://europepmc.org/article/MED/36460017>, <https://clinicaltrials.gov/study/NCT02908672> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(22)00687-8> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Ascierto PA, Stroyakovskiy D, Gogas H, et al." ;
  onco:trials <https://onco.cc/trials/imspire150/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .